Ascletis completes enrollment for US obesity treatment study

Ascletis Pharma Inc. has completed enrollment for its U.S. Phase IIa study of ASC30, an once-monthly subcutaneous depot formulation for obesity treatment. The study, NCT06679959, involves 65 participants who are obese or overweight with at least one weight-related comorbidity. Topline data from this 12-week randomized, double-blind, placebo-controlled, and multi-center study are anticipated in the first quarter of 2026.

ASC30, a small molecule GLP-1R agonist, previously demonstrated a 46-day observed half-life in a Phase Ib study, supporting its once-monthly administration. The proprietary SQ depot slow-release formulation leverages Ascletis' Ultra-Long-Acting Platform (ULAP), which avoids the limitations of albumin-dependent half-life extension technologies.

ASC30 is an investigational GLP-1R biased small molecule agonist with U.S. and global compound patent protection until 2044. The company will host a conference call today, October 20, 2025, at 10:00 a.m. China Standard Time to discuss this development.